Argireline

Argireline was developed as a biomimetic peptide modelled on the N-terminal end of SNAP-25, a protein that plays a critical role in the vesicle fusion process responsible for neurotransmitter release. When applied topically, Argireline competes with SNAP-25 for a position within the SNARE complex — the molecular machinery that triggers muscle contraction. By partially destabilising this complex, the peptide reduces the release of acetylcholine, resulting in a localised, reversible reduction of muscle activity in the treated area. Clinical studies have demonstrated that Argireline reduces wrinkle depth by up to 30% after 30 days of treatment in formulations containing 10% of the hexapeptide. Additional research published in peer-reviewed journals confirmed improvements in the histological structure of skin tissue, including measurable increases in type I collagen and reductions in type III collagen — markers consistent with younger, healthier skin architecture. These results establish Argireline as one of the most evidence-based actives in cosmetic anti-aging science. Unlike injectable botulinum toxin, Argireline carries no risk of systemic toxicity, requires no medical administration, and delivers a gradual, natural-looking result that accumulates with consistent use. Its safety profile has been thoroughly evaluated, with studies confirming no in vivo oral toxicity and no primary irritation even at high doses — making it suitable for sensitive skin and for use in post-treatment care protocols where skin resilience may be temporarily reduced.